Paper37686553
Recurrent Glioblastoma: A Review of the Treatment Options.
Vaz-Salgado MA and 12 others. Cancers (Basel), 2023. Cited by 126 papers, by iCite.
Cite this record
ConductScience Library. Recurrent Glioblastoma: A Review of the Treatment Options. Papers, record 37686553. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37686553
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References132
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31122294 | The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma. | J Exp Clin Cancer Res | 2019 | https://conductscience.org/library/papers/31122294 | PubMed |
| 2 | 28575464 | Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification. | Neuro Oncol | 2017 | https://conductscience.org/library/papers/28575464 | PubMed |
| 3 | 34559423 | Treatment options for progression or recurrence of glioblastoma: a network meta-analysis. | Cochrane Database Syst Rev | 2021 | https://conductscience.org/library/papers/34559423 | PubMed |
| 4 | 30500939 | A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma. | Neuro Oncol | 2019 | https://conductscience.org/library/papers/30500939 | PubMed |
| 5 | 32200460 | Proton therapy re-irradiation preserves health-related quality of life in large recurrent glioblastoma. | J Cancer Res Clin Oncol | 2020 | https://conductscience.org/library/papers/32200460 | PubMed |
| 6 | 17576523 | Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients. | J Neurooncol | 2008 | https://conductscience.org/library/papers/17576523 | PubMed |
| 7 | 22837387 | Transforming fusions of FGFR and TACC genes in human glioblastoma. | Science | 2012 | https://conductscience.org/library/papers/22837387 | PubMed |
| 8 | 19720927 | Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. | J Clin Oncol | 2009 | https://conductscience.org/library/papers/19720927 | PubMed |
| 9 | 35864254 | Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial. | Nat Med | 2022 | https://conductscience.org/library/papers/35864254 | PubMed |
| 10 | 18588890 | Hypoxia-inducible factor-1alpha regulates matrix metalloproteinase-1 activity in human bone marrow-derived mesenchymal stem cells. | FEBS Lett | 2008 | https://conductscience.org/library/papers/18588890 | PubMed |
| 11 | 31747009 | INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. | Neuro Oncol | 2020 | https://conductscience.org/library/papers/31747009 | PubMed |
| 12 | 33838625 | Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas. | N Engl J Med | 2021 | https://conductscience.org/library/papers/33838625 | PubMed |
| 13 | 30266892 | A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma. | Oncologist | 2019 | https://conductscience.org/library/papers/30266892 | PubMed |
| 14 | 28426845 | HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial. | JAMA Oncol | 2017 | https://conductscience.org/library/papers/28426845 | PubMed |
| 15 | 24764576 | Oncolytic viruses and their application to cancer immunotherapy. | Cancer Immunol Res | 2014 | https://conductscience.org/library/papers/24764576 | PubMed |
| 16 | 29445288 | Prognostic significance of epidermal growth factor receptor expression in glioma patients. | Onco Targets Ther | 2018 | https://conductscience.org/library/papers/29445288 | PubMed |
| 17 | 31750274 | Preclinical And Clinical Development Of Oncolytic Adenovirus For The Treatment Of Malignant Glioma. | Oncolytic Virother | 2019 | https://conductscience.org/library/papers/31750274 | PubMed |
| 18 | 18525321 | Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience. | Anticancer Drugs | 2008 | https://conductscience.org/library/papers/18525321 | PubMed |
| 19 | 35849035 | Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial. | Neuro Oncol | 2023 | https://conductscience.org/library/papers/35849035 | PubMed |
| 20 | 34498213 | Efficacy of osimertinib plus bevacizumab in glioblastoma patients with simultaneous EGFR amplification and EGFRvIII mutation. | J Neurooncol | 2021 | https://conductscience.org/library/papers/34498213 | PubMed |
Cited by104
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 126 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42893563 | AI-bioinformatics synergy for precision medicine in brain diseases: integrating radiomics and multi-omics data. | Brief Bioinform | 2026 | https://conductscience.org/library/papers/42893563 | PubMed |
| 42857743 | Gallium maltolate causes genomic instability to enhance glioblastoma response to radiation and temozolomide. | Neurooncol Adv | 2026 | https://conductscience.org/library/papers/42857743 | PubMed |
| 42852014 | Reassessing Viral Gene Therapy for Glioblastoma: Translational Opportunities and Challenges. | Yale J Biol Med | 2026 | https://conductscience.org/library/papers/42852014 | PubMed |
| 42824982 | Receptor tyrosine kinase targeted therapies in glioblastoma: a systematic review. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/42824982 | PubMed |
| 42724833 | FET-PET vs. MRI in re-irradiation of recurrent glioblastoma: no added benefit, but key insights for the future. | Transl Cancer Res | 2026 | https://conductscience.org/library/papers/42724833 | PubMed |
| 42698902 | Toward functional precision oncology: organotypic brain slices in glioblastoma. | Front Oncol | 2026 | https://conductscience.org/library/papers/42698902 | PubMed |
| 42694176 | Comparative efficacy of therapeutic strategies for recurrent or refractory glioblastoma: a systematic review and network meta-analysis. | Front Neurol | 2026 | https://conductscience.org/library/papers/42694176 | PubMed |
| 42588736 | Reduced-Dose Regorafenib for Recurrent Glioblastoma: A Safety and Outcome Analysis. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42588736 | PubMed |
| 42558850 | Glioblastoma stem cells as carriers of tumour memory: a strategy for personalised immunotherapy using tumour-infiltrating lymphocytes. | Front Immunol | 2026 | https://conductscience.org/library/papers/42558850 | PubMed |
| 42549406 | Targeting replication stress in glioblastoma: From genotoxic treatment and inhibitors of the DNA damage response to immunotherapy. | Neurooncol Adv | 2026 | https://conductscience.org/library/papers/42549406 | PubMed |
| 42524459 | C3G Downregulation Enhances Stemness in Glioblastoma Cells by Promoting PKM2 Upregulation. | Int J Biol Sci | 2026 | https://conductscience.org/library/papers/42524459 | PubMed |
| 42493681 | Salvage therapies for recurrent grade 4 IDH-wildtype glioma: a BRAIN Registry analysis of real-world treatment patterns. | J Neurooncol | 2026 | https://conductscience.org/library/papers/42493681 | PubMed |
| 42449033 | Hydrogel-Mediated Delivery of Drug Nanocarriers in the Oedematous Postoperative Brain. | Pharm Res | 2026 | https://conductscience.org/library/papers/42449033 | PubMed |
| 42368382 | Prognostic impact of circulating vitamin D and genetic variants in the vitamin D pathway in glioblastoma. | Neurooncol Adv | 2026 | https://conductscience.org/library/papers/42368382 | PubMed |
| 42251229 | Post-recurrence management of malignant glial brain tumors: therapeutic strategies, evidence and limitations, palliative care, terminal sedation, and end-of-life considerations. | Clin Transl Oncol | 2026 | https://conductscience.org/library/papers/42251229 | PubMed |
| 42238672 | Role of Bevacizumab in Multiple Glioblastomas: A Retrospective Single-Center Analysis. | Neurosciences (Riyadh) | 2026 | https://conductscience.org/library/papers/42238672 | PubMed |
| 42201434 | Precision reirradiation in recurrent CNS tumors integrating biology techniques and multimodal care. | Discov Oncol | 2026 | https://conductscience.org/library/papers/42201434 | PubMed |
| 42158948 | Network-driven prioritization and functional phenotyping nominate TTC23 as a biomarker-informed target in chlorpromazine repurposing for glioblastoma. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42158948 | PubMed |
| 42121885 | The Multifaceted Role of microRNA-10b (miR-10b) in Glioblastoma: From Oncogenic Driver to Therapeutic Target. | Cells | 2026 | https://conductscience.org/library/papers/42121885 | PubMed |
| 42101535 | Glioblastoma: epidemiology, molecular pathogenesis, diagnosis, management, and therapeutic resistance. | Mol Biomed | 2026 | https://conductscience.org/library/papers/42101535 | PubMed |
Genes44
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37686553
GET https://conductscience.org/api/papers/v1/37686553/references?page=2